Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $162.50 short call and a strike $167.50 long call offers a potential 16.55% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $162.50 by expiration. The full premium credit of $0.71 would be kept by the premium seller. The risk of $4.29 would be incurred if the stock rose above the $167.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 34.27 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Influencers with Andy Serwer: Geoff Martha
Thu, 02 Dec 2021 11:00:00 +0000
In this episode of Influencers, Andy is joined by Medtronic Chairman & CEO Geoff Martha as they discuss Geoff taking the reins at the height of the pandemic, how supply chain issues have hurt manufacturing, and Geoff’s experience building ventilators with Elon Musk.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Wed, 01 Dec 2021 22:45:10 +0000
In the latest trading session, Johnson & Johnson (JNJ) closed at $158.08, marking a +1.38% move from the previous day.
U.S. administers 462.3 mln doses of COVID-19 vaccines – CDC
Wed, 01 Dec 2021 22:44:10 +0000
The United States has administered 462,263,845 doses of COVID-19 vaccines in the country as of Wednesday morning and distributed 575,721,925 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 460,773,508 vaccine doses the CDC said had gone into arms by Nov. 30 out of 573,238,255 doses delivered. The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech , as well as Johnson & Johnson's one-shot vaccine.
Jim Cramer: Buying the tech dip is a mistake when these 4 stocks offer ‘easier money’
Wed, 01 Dec 2021 20:45:00 +0000
Each of these stocks has been “trampled on unjustly,” the Mad Money host says.
CDC isn’t changing fully vaccinated definition to include boosters ‘right now’
Wed, 01 Dec 2021 20:39:00 +0000
The CDC is encouraging all eligible people to get COVID booster shots, but it's not considering boosters when labeling a person ‘fully vaccinated'
Also on Market Tamer…
Follow Us on Facebook